Due to the fact that SARS-CoV and 2019-nCoV both use ACE2 for cell entry, we can speculate that for COVID-19, ACE2 may also be downregulated by 2019-nCoV binding to ACE2, while the activation of the ACE-Ang II axis will promote lung injury. This evidence concerns the gene ACE2 and COVID-19.